---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-007063"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:15:07.914705+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Xilio reports $137.5M cash, appoints chair, gets $35.8M from warrants

## Summary
- Cash $137.5M at Dec 31, 2025, including $35.8M from Series B warrants; runway into Q2 2027.
- Full exercise of Series B warrants by Coastlands Capital, Frazier Life Sciences, and Gilead.
- Achieved milestone for masked antibody program under AbbVie; nominated CLDN18.2 T cell engager candidate.
- Appointed Sara Bonstein as board chair, succeeding Paul Clancy who retired Jan 6, 2026.
- Pipeline milestones: IND for XTX501 mid-2026, initial Phase 1 data H2 2027, STEAP1 candidate H1 2026.

## SEC filing metadata
- accession: 0001193125-26-007063
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000119312526007063/0001193125-26-007063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000119312526007063/xlo-20260108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-007063
- JSON: https://secwatch.observer/filing/0001193125-26-007063.json
- Plain text: https://secwatch.observer/filing/0001193125-26-007063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.